Genomic Vision is Accelerating Its Clinical Trial in Cervical Cancer with an Additional Study in the Czech Republic
July 20 2016 - 11:45AM
Business Wire
- Internationalization of the HPV
clinical trial with the participation of two reputed Czech
hospitals
- The first patients are currently being
enrolled
- Interim results are expected in early
2017
Genomic Vision (FR0011799907 – GV), DNA molecular combing
specialist that develops tests for the diagnostics market and tools
for the life sciences research market, today announces the first
enrollments in the clinical trial being organized in the Czech
Republic aimed at validating the integration of the oncogenic, i.e.
high-risk, human papillomavirus (HPV-HR) as an indicator of the
severity of cervical lesions.
This trial is being undertaken in two major hospitals, the Brno
Centre for Outpatient Gynaecology and Primary Care (Dr. Vladimír
Dvořák) and the Brno University Hospital (Prof. Pavel Ventruba),
and foresees the inclusion of 993 female patients. The primary
end-point of this study is to prove that the integration of HPV is
a biomarker for diagnosing high-risk precancerous lesions that
require appropriate treatment to be defined. The initial results of
this pilot study are expected in early 2017.
Aaron Bensimon, Genomic Vision’s co-founder and Chairman,
comments: “We wanted to launch this study simultaneously with
the IDAHO trial, currently being undertaken with Reims University
Hospital and other French medical centers, in order to accelerate
and internationalize our HPV test development program. Indeed,
following feedback from clinicians, it is clear that there is a
real need for more specific diagnostic tests capable of detecting
high-grade precancerous lesions that are likely to evolve into
cancerous lesions in the cervix. Thanks to a high enrollment pace,
the initial results of this study will be available by the
beginning of 2017.”
The integration of HPV DNA in a host’s genome is considered to
be a key event in the progression of precancerous lesions into
cancerous lesions in the cervix. The aim of this study is to
determine whether the integration of HPV-HR DNA in patients’
genomes is a sufficient indicator of diagnostics, i.e. of the
severity of lesions. Genomic Vision’s molecular combing technique
is currently the only one that allows the frequency of the
integration of high-risk HPV-HR to be detected, in a direct and
high resolution manner.
Dr. Dvořák, Head Physician at the Brno Centre for Outpatient
Gynaecology and Primary Care, and principal investigator for the
study, adds: “HPV infection, which is in some cases related to
cervical cancer, is one of main threats to women´s health. Every
improvement in diagnostics is very important, as it can influence
the treatment program for each individual patient. For these
reasons, I have agreed to participate in the HPV trial organized by
Genomic Vision. Should its positive results be confirmed,
physicians will have access to a new tool enabling them to more
accurately predict the severity of HPV infection with regard to the
development of cervical cancer.”
Upcoming financial publication
2016 half-year results, Tuesday, July 26, 2016 (after
trading)
ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a DNA molecular combing
specialist that develops tests for the diagnostics market and tools
for the life sciences research market. Using its innovative
technology that allows the direct visualization of individual DNA
molecules, Genomic Vision detects quantitative and qualitative
variations in the genome that are at the origin of numerous serious
pathologies. The Company is developing a solid portfolio of tests
that initially target breast and colon cancers. Since 2013, the
Company has marketed the CombHelix FSHD test for identifying
facioscapulohumeral dystrophy (FSHD), a myopathy that is difficult
to detect. It is marketed in the United States through a strategic
alliance with Quest Diagnostics, the American leader in diagnostic
laboratory tests, and in France directly by the Company. Genomic
Vision has been listed on Compartment C of Euronext Paris since
April 2014.
ABOUT MOLECULAR COMBING
DNA molecular combing technology significantly improves the
structural and functional analysis of DNA molecules. DNA fibers are
stretched over glass slides, as if "combed", and uniformly aligned
over the entire surface. It is then possible to identify genetic
anomalies by locating specific genes or sequences in the patient's
genome using genetic markers, a technique developed by Genomic
Vision and patented under the name Genomic Morse Code. This
exploration of the entire genome at high resolution via a simple
analysis enables the direct visualization of genetic anomalies that
are undetectable by other technologies.
For further information, please go to: www.genomicvision.com
Member of CAC® Mid & Small, CAC® All-Tradable
and EnterNext© PEA-PME 150 indexes
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160720005871/en/
Genomic VisionAaron Bensimon, +33-1-4908-0750Co-founder,
Chairman &
CEOinvestisseurs@genomicvision.comorKalimaRelations
PresseEstelle Reine-Adélaïde, +33-6-1772-7473Florence Calba,
+33-1-4490-8254era@kalima-rp.frorLHAInvestor Relations
USAnne Marie Fields,
212-838-3777SVPafields@lhai.comorNewCapInvestor Relations /
Strategic CommunicationsDušan Orešanský / Emmanuel Huynh,
+33-1-4471-9492gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Goldfield (AMEX:GV)
Historical Stock Chart
From Mar 2023 to Mar 2024